Sigachi Industries LtdQ1 FY27
Sigachi Industries Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹32.5P/E: 30.6Market Cap: ₹995 CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter.
- →Full-year revenue guidance remains INR650-675 crores, with expectations to reach INR160-170 crores in quarterly run rate by Q4 FY27.
- →Capacity expansion underway with debottlenecking and adding equipment to increase volumes beyond current 18,000 MT.
- →New capacities with Dahej 2 and CCS facility expected by FY28 to further increase volumes.
- →API segment revenues expected to ramp up from INR21 crores in Q1 to higher levels in subsequent quarters through new high-margin products.
- →Product mix improvements with co-processed excipients and differentiated products to enhance revenue and margins.
- →Export demand expected to remain key driver, especially in MCC and CCS segments.
- →Overall margin trajectory target is 18% EBITDA for the full year.
Margin guidance
Category 1- →Revenue guidance for FY27 remains at INR650-675 crores, with quarter-on-quarter improvement expected.
- →Full-year EBITDA margin is targeted at 18%, up from around 13% currently, with Q4 margins anticipated to exceed 20%.
- →MCC segment capacity utilization expected to increase with debottlenecking and capacity enhancement, supporting revenue growth.
- →API business projected to ramp up to INR90-100 crores annually, with higher-margin molecules contributing to profitability.
- →Operating leverage and fixed costs stability to drive margin expansion as revenues grow.
- →Strategic focus on expanding capacity, product mix improvement, and disciplined execution to sustain profitable growth.
- →Capex of over INR100 crores in FY27 and INR150-200 crores in FY28 planned, funded through internal accruals, borrowings, and possible equity raise.
- →Receivable days targeted to improve from ~93-94 to 90 days by year-end, enhancing working capital efficiency.
Fundraise plans
Yes- →The company is planning significant capex of around INR100 crores in FY27 and INR150-200 crores in FY28.
- →To fund this, options include bank borrowings (term loans) and raising funds through preferential equity issuance.
- →No term loans are currently outstanding, but banks are ready to provide loans if needed.
- →The company is considering a preferential equity raise and will make an announcement once finalized.
- →If the insurance claim (expected around September) is delayed, capex may be impacted but can be managed through alternate funding options like loans or equity.
- →Past preferential share issue saw promoter shares forfeited; the company is mindful of ensuring timely payment in future fundraises.
- →Overall, a fundraising through a mix of debt and equity is anticipated in the near future to support expansion plans.
Order book
- →Sigachi Industries is currently receiving orders for the supply of CCS (Co-Processed Superdisintegrants) from export customers, even before the CCS production capacity is operational.
- →Inquiries are coming from foreign customers, likely due to market shortages and existing customer requirements for CCS alongside MCC.
- →The company expects more orders from exports once the CCS facility is operational (planned for FY28).
- →There is no explicit mention of overall current orderbook value or pending order backlog figures in the transcript.
- →Strong demand is indicated by inquiries and order interest despite current capacity bottlenecks.
Capex plans
Yes- →Ongoing capex for FY27 is around INR 100 crores, with an additional INR 150-200 crores planned for FY28.
- →Capex focuses on increasing capacity through debottlenecking, adding equipment (shifters, blenders), and product mix enhancements, especially in MCC.
- →New capacity expansions include increasing MCC capacity from 18,000 to 30,000 metric tons in upcoming quarters.
- →Dahej 2 plant expansion is progressing, expected operational by Q2 FY28 (delayed from earlier Q1 FY28 expectation).
- →CCS (Continuous Coating System) facility is expected to be fully operational in FY28.
- →Funding for capex may come from internal accruals, borrowings (bank finance/term loans), and potential preferential equity issuance.
- →Insurance claim (~INR16.5 crores) expected by September 2026 will support capex but delays won't hamper as alternate funding options exist.
- →Additional future capacity expansions are planned, with announcements forthcoming once finalized.
Track Sigachi Industries Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- →Revenue guidance for FY27 remains at INR650-675 crores, with quarter-on-quarter improvement expected.
- →Full-year EBITDA margin is targeted at 18%, up from around 13% currently, with Q4 margins anticipated to exceed 20%.
- →MCC segment capacity utilization expected to increase with debottlenecking and capacity enhancement, supporting revenue growth.
- →API business projected to ramp up to INR90-100 crores annually, with higher-margin molecules contributing to profitability.
- →Operating leverage and fixed costs stability to drive margin expansion as revenues grow.
- →Strategic focus on expanding capacity, product mix improvement, and disciplined execution to sustain profitable growth.
- →Capex of over INR100 crores in FY27 and INR150-200 crores in FY28 planned, funded through internal accruals, borrowings, and possible equity raise.
- →Receivable days targeted to improve from ~93-94 to 90 days by year-end, enhancing working capital efficiency.
Order book
- →Sigachi Industries is currently receiving orders for the supply of CCS (Co-Processed Superdisintegrants) from export customers, even before the CCS production capacity is operational.
- →Inquiries are coming from foreign customers, likely due to market shortages and existing customer requirements for CCS alongside MCC.
- →The company expects more orders from exports once the CCS facility is operational (planned for FY28).
- →There is no explicit mention of overall current orderbook value or pending order backlog figures in the transcript.
- →Strong demand is indicated by inquiries and order interest despite current capacity bottlenecks.
How does Sigachi Industries Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Sigachi Industries Ltd
Rev 2Mar 1
See full Pharmaceuticals & Biotechnology sector rankings
How does Sigachi Industries Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sigachi Industries Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.